The M11 089 study was recently published in the Journal of Clinical Oncology. Beaumont RCSI Cancer Centre contributed to the 970 patients that were randomised to receive platinum-based chemotherapy with veliparib or placebo. The study concluded that there was no therapeutic benefit of adding veliparib to first-line chemotherapy for patients with squamous Non-Small Cell Lung Cancer (NSCLC). The researchers did however find a signature in archival tissue samples that may identify a sub group of patients likely to derive benefit from veliparib in combination with chemotherapy.

J Clin Oncol. 2021 Nov 10;39(32):3633-3644. doi: 10.1200/JCO.20.03318. Epub 2021 Aug 26. PMID: 34436928; PMCID: PMC8577684

The final results of the long running phase III SOLE study (Study of Letrozole Extension) were recently published in the Annals of Oncology.  Beaumont RCSI Cancer Centre contributed to the 4851 patients that were randomised globally. The study concluded that extended adjuvant endocrine therapy by intermittent administration of letrozole did not improve disease free survival (DFS) compared with continuous use. However, the similar DFS coupled with previously reported quality-of-life advantages suggest intermittent extended treatment is a valid option for patients who require or prefer a treatment interruption.

Ann Oncol. 2021 Oct;32(10):1256-1266. doi: 10.1016/j.annonc.2021.07.017. Epub 2021 Aug 10. PMID: 34384882